resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 9th Annual Leerink Partners Global Healthcare Conference in New York City on Thursday, February 27, 2019 at 10:00 AM ET.
BOSTON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 9th Annual Leerink Partners Global Healthcare Conference in New York City on Thursday, February 27, 2019 at 10:00 AM ET.
A live audio webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors. An archived replay will be available for 30 days following the presentation.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to treat aging-related diseases. resTORbio’s lead program selectively inhibits TORC1, an evolutionarily conserved pathway that contributes to the decline in function of aging organ systems, including neurologic function. Learn more about resTORbio, Inc. at www.resTORbio.com.
Investor Contact
Lauren Stival
Stern Investor Relations, Inc.
212-362-1200
lauren.stival@sternir.com
Media Contact
Karen Sharma
MacDougall
781-235-3060
ksharma@macbiocom.com
